C22.1
BillableIntrahepatic bile duct carcinoma
Last updated: FY2026 ICD-10-CM (Oct 1, 2025 – Sep 30, 2026) | CMS-HCC V28 (100% phase-in, PY2026)
Is C22.1 an HCC code?
Yes. C22.1 maps to Lung and Other Severe Cancers under the CMS-HCC V28 risk adjustment model (and Lung and Other Severe Cancers under V24).
HCC Category Mapping
RAF weights shown are the community, non-dual, aged base weights from the CMS risk adjustment model file. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.
MEAT Criteria for C22.1
For C22.1 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically — it has to be re-documented and supported each calendar year.
- MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
- EEvaluate: test results, medication response, or physical findings reviewed by the provider
- AAssess: explicit mention in the assessment or plan with acknowledgment of status
- TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis
Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C22.1 during that encounter — not just copy-forwarded from a problem list.
What This Code Means
C22.1 is the ICD-10-CM diagnosis code for intrahepatic bile duct carcinoma. A cancer that develops in the bile ducts inside the liver. This is a rare type of liver cancer distinct from hepatocellular carcinoma. C22.1 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of digestive organs (c15-c26).
Under the CMS-HCC V28 risk adjustment model, C22.1 maps to Lung and Other Severe Cancers (HCC 20) with a community, non-dual, aged base RAF weight of 0.000. Under the older V24 model, C22.1 mapped to the same category but with a base RAF weight of 0.973 — V28 recalibrated weights across the entire model. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.
Ensure documentation confirms intrahepatic location (inside liver) versus extrahepatic bile ducts. Because C22.1 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.
HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C22.1 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.
Coding Tips
- •Ensure documentation confirms intrahepatic location (inside liver) versus extrahepatic bile ducts
- •Note any associated conditions like primary sclerosing cholangitis or liver fluke infection
Clinical Significance
Intrahepatic cholangiocarcinoma (bile duct carcinoma within the liver) is the second most common primary liver malignancy and is increasing in incidence globally. It is a highly aggressive cancer with limited treatment options and a poor prognosis, with five-year survival rates typically below 10% for advanced disease. Accurate distinction from hepatocellular carcinoma and extrahepatic cholangiocarcinoma is critical because treatment approaches differ significantly.
Documentation Requirements
- ✓Pathological confirmation of intrahepatic cholangiocarcinoma (bile duct origin within the liver)
- ✓Distinction from hepatocellular carcinoma and mixed tumors
- ✓Stage of disease
- ✓Any associated conditions (primary sclerosing cholangitis, liver fluke infection, hepatolithiasis)
- ✓Molecular markers if tested (isocitrate dehydrogenase mutations, fibroblast growth factor receptor fusions)
Excludes 1 — Do NOT code together
- malignant neoplasm of hepatic duct (C24.0)